Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human EGFRvIII, Avi Tag (Avitag™), His tag, 25µg  

Recombinant Biotinylated Human EGFRvIII, Avi Tag (Avitag™), His tag, 25µg

Recombinant Biotinylated Human EGFRvIII, Leu 25 - Ser 378, expressed from human 293 cells (HEK293), His,Avitag™ (MALS verified)

Synonym
recombinant, human, biotinylated, protein, EGFR, ERBB, ERBB1, HER1, PIG61, mENA,EGFRvIII

More details

EGR-H82E0-25

Availability: within 7 days

481,00 €

Background
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.
The type III EGF deletion-mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors; EGFR gene amplification is correlated with the structural rearrangement of the gene. The EGFRvIII gene has an in-frame deletion of 801 base pairs, corresponding to exons 2–7 in the mRNA, resulting in the deletion of amino acids 30-297 in the extracellular domain and the generation of a glycine at the fusion point.

Source
Recombinant Biotinylated Human EGFRvIII, His,Avitag(EGR-H82E0) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 378 (Accession # NP_001333870.1).
Predicted N-terminus: Leu 25

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™)
The protein has a calculated MW of 42.2 kDa. The protein migrates as 60-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio

Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
 
Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity"
Ho, Qiu, Miller et al
Biomed Pharmacother (2022) 157, 114047
(2) "Identification of a novel peptide ligand for the cancer-specific receptor mutation EGFRvIII using high-throughput sequencing of phage-selected peptides"
Mansour, Adhya, Lebleu et al
Sci Rep (2022) 12 (1), 20725
(3) "Engineered anti-EGFRvIII targeted exosomes induce apoptosis in glioblastoma multiforme"
Rahmani, Kiani, Tong et al
J Drug Target (2022)
Showing 1-3 of 1093 papers.